Tyrosine Kinase Inhibitors: all 10,469 studies that test it
Page 3 of 105. Open to participants first (1,909), then studies with results posted, then the rest; newest registration first within each.
- Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment - 1RecruitingNCT07598643Phase 2
- Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental VitiligoNot yet recruitingNCT07595939Phase 3
- AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCLNot yet recruitingNCT07594899Phase 2
- Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaNot yet recruitingNCT07594548Phase 1
- Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy MaintenanceRecruitingNCT07594015Phase 2
- A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal CancerNot yet recruitingNCT07591597Phase 1/2
- daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCTNot yet recruitingNCT07588945Phase 3
- A Trial of Upadacitinib for Non-responsive Eosinophilic EsophagitisRecruitingNCT07588568Phase 2
- A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLCRecruitingNCT07586202Phase 2
- A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and LenalidomideNot yet recruitingNCT07585747Phase 2
- A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)RecruitingNCT07585266Phase 3
- Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone LymphomaRecruitingNCT07583810Phase 2
- Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF)Not yet recruitingNCT07583589Phase 2
- Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNot yet recruitingNCT07582159Phase 2
- Comparison of Methotrexate and Tofacitinib in Chronic Plaque PsoriasisNot yet recruitingNCT07581418Not applicable
- Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on ImmunotherapyNot yet recruitingNCT07578025Phase 2
- Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell CarcinomaRecruitingNCT07571551Phase 2
- A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaRecruitingNCT07570017Phase 1
- Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract CancerRecruitingNCT07569679Phase 2
- A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) SyndromeNot yet recruitingNCT07569081Phase 2/3
- A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLCRecruitingNCT07562581Phase 2
- Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)Not yet recruitingNCT07560410Phase 1/2
- Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard TreatmentRecruitingNCT07559864Phase 2
- Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated MalariaRecruitingNCT07559370Phase 2
- Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingNCT07557056Phase 2
- Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT LymphomaRecruitingNCT07554898Phase 2
- Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIALRecruitingNCT07554820Phase 4
- Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and AdolescentsRecruitingNCT07554495Phase 3
- OLE Study With Filgotinib in JIARecruitingNCT07553182Phase 3
- Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric CancerRecruitingNCT07552402Not applicable
- A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk MyelofibrosisRecruitingNCT07551427Phase 2
- Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）RecruitingNCT07550673Phase 4
- Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibitors: A Prospective, Multicenter, Real-World StudyNot yet recruitingNCT07550452Not applicable
- Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid LeukemiaNot yet recruitingNCT07549464Phase 1
- Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLCNot yet recruitingNCT07549061Phase 2
- Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell TransplantationRecruitingNCT07548983Phase 1
- Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)Not yet recruitingNCT07548450Phase 2
- Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye DiseaseRecruitingNCT07547930Phase 2
- A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein ExpressionRecruitingNCT07546500Phase 3
- Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis（UPFRONT）RecruitingNCT07546097Phase 4
- Therapeutics for Moderate and Severe DengueNot yet recruitingNCT07543458Phase 3
- GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.Not yet recruitingNCT07540390Phase 3
- A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung CancerNot yet recruitingNCT07538271Phase 2
- Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung CancerNot yet recruitingNCT07538258Phase 2
- Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted TherapyNot yet recruitingNCT07537777Phase 2
- A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular CarcinomaNot yet recruitingNCT07535840Not applicable
- Baricitinib for Post-HSCT Persistent ThrombocytopeniaRecruitingNCT07535645Phase 1/2
- A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung CancerRecruitingNCT07535437Phase 1/2
- A Phase 2/3 Study of Brepocitinib in Adults With Lichen PlanopilarisRecruitingNCT07532603Phase 2/3
- A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe AsthmaRecruitingNCT07532265Phase 2
- Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar PustulosisNot yet recruitingNCT07530367Phase 3
- Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted TherapyRecruitingNCT07528716Phase 3
- A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory NeuroblastomaNot yet recruitingNCT07527169Phase 2
- Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)RecruitingNCT07525466Phase 1/2
- A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALLNot yet recruitingNCT07522801Phase 2
- Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in MyelofibrosisRecruitingNCT07521046Phase 1
- Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow MarginNot yet recruitingNCT07518706Phase 2
- Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II TrialNot yet recruitingNCT07517640Phase 2
- Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 StudyRecruitingNCT07516132Phase 3
- Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLLRecruitingNCT07516093Phase 3
- Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma PatientsNot yet recruitingNCT07514455Phase 2
- Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC TrialNot yet recruitingNCT07514429Phase 2
- Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular CarcinomaNot yet recruitingNCT07511504Phase 2
- Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K)Not yet recruitingNCT07510932Phase 2
- A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NECNot yet recruitingNCT07510594Phase 2
- TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal ResponseRecruitingNCT07510191Phase 4
- Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)RecruitingNCT07509749Phase 2
- Deucravacitinib in the Treatment of Cicatricial AlopeciasRecruitingNCT07508488Phase 2
- Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell CarcinomaRecruitingNCT07505186Phase 2
- Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative ColitisNot yet recruitingNCT07502339Phase 4
- Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Not yet recruitingNCT07501169Phase 2
- Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell CarcinomaNot yet recruitingNCT07500831Not applicable
- Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)RecruitingNCT07499362Phase 2
- Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationRecruitingNCT07499271Phase 2
- Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior TreatmentRecruitingNCT07498478Phase 2
- Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell CountsNot yet recruitingNCT07498205Phase 4
- Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)Not yet recruitingNCT07495579Phase 2
- Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCLNot yet recruitingNCT07493330Phase 1/2
- Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Randomized Placebo-controlled Study.RecruitingNCT07492251Phase 2
- Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCCNot yet recruitingNCT07490002Phase 2
- TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) PatientsNot yet recruitingNCT07489755Phase 3
- A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)RecruitingNCT07489495Phase 3
- Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen PlanopilarisRecruitingNCT07487948Phase 2
- Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without PembrolizumabRecruitingNCT07486817Phase 2
- A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung CancerNot yet recruitingNCT07485920Phase 4
- Boosting Osimertinib Blood Brain Barrier PenetrationRecruitingNCT07485452Phase 2
- H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)Not yet recruitingNCT07484139Phase 2
- Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural EffusionNot yet recruitingNCT07482605Phase 2
- KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal CancerRecruitingNCT07481058Phase 2
- To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment SubjectsRecruitingNCT07480824Phase 1
- Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)RecruitingNCT07478991Phase 3
- A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaRecruitingNCT07477457Phase 2
- A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of RecurrenceRecruitingNCT07475026Phase 3
- SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell CarcinomaNot yet recruitingNCT07470840Phase 2
- Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid CancerNot yet recruitingNCT07470489Phase 2
- Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic CancerNot yet recruitingNCT07469956Phase 2
- A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsRecruitingNCT07469891Phase 1
- An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell CarcinomaRecruitingNCT07469683Phase 2
- MRD-guided Maintenance Post-HCT: Gilteritini vs SorafenibRecruitingNCT07463651Phase 3
- Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatmentNot yet recruitingNCT07460206Phase 2